Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Sotera Health ( (SHC) ) is now available.
On January 12, 2026, Sotera Health presented at the 44th Annual J.P. Morgan Healthcare Conference in Cleveland, providing a business update and announcing that 2025 revenue was expected to surpass $1.16 billion, representing at least 5.5% year-over-year growth, or 5.0% on a constant-currency basis. The company highlighted that this performance would mark more than 20 consecutive years of annual revenue growth, underscoring the durability of its business model and financial profile, and signaled continued operational momentum ahead of its full-year 2025 results and 2026 outlook, scheduled for release on February 24, 2026.
The most recent analyst rating on (SHC) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Sotera Health stock, see the SHC Stock Forecast page.
Spark’s Take on SHC Stock
According to Spark, TipRanks’ AI Analyst, SHC is a Neutral.
Sotera Health’s overall stock score is driven by strong earnings call performance and positive technical indicators, reflecting robust revenue growth and improved financial stability. However, high valuation and financial performance concerns, such as low profitability and high debt levels, moderate the score.
To see Spark’s full report on SHC stock, click here.
More about Sotera Health
Sotera Health Company is a leading global provider of mission-critical, end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, operating through its Sterigenics, Nordion and Nelson Labs businesses with a focus on safeguarding global health.
Average Trading Volume: 2,338,068
Technical Sentiment Signal: Buy
Current Market Cap: $5.34B
For an in-depth examination of SHC stock, go to TipRanks’ Overview page.